Biblio Discovery — Demo Discovery Service

4 hasil untuk "David Aluga"

Menampilkan 1–4 · 0,29 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Socioeconomic determinants of teenage pregnancy and early motherhood in the United Kingdom: A perspective

    David Aluga; Elvis Anyaehiechukwu Okolie

    Health Promotion Perspectives, Vol. 11 No. 4 · 2021 · Inggris · DOAJ Scopus

    The United Kingdom has one of the highest teenage birth rates among countries in western Europe. Government initiatives such as the Teenage Pregnancy Strategy introduced by the labor government in 1999 to reduce the teenage pregnancy rate by half in ten years could be responsible for the steady…

  2. Artikel Jurnal

    Comparative analysis of co-processed starches prepared by three different methods

    Yonni Apeji; David Aluga; Olubunmi Olayemi dkk.

    British Journal of Pharmacy, Vol. 2 No. 1 · 2017 · Inggris · DOAJ

    Co-processing is currently of interest in the generation of high-functionality excipients for tablet formulation. In the present study, comparative analysis of the powder and tableting properties of three co-processed starches prepared by three different methods was carried out. The co-processed…

  3. Artikel Jurnal

    Factors influencing cervical cancer screening practice among female health workers in Nigeria: A systematic review

    Elvis Anyaehiechukwu Okolie; Debra Barker; Lawrence Achilles Nnyanzi dkk.

    Cancer Reports, Vol. 5 No. 5 · 2022 · Inggris · DOAJ Scopus

    Abstract Background Cervical cancer is the most prevalent gynaecologic cancer in Nigeria. Despite being largely preventable through screening, cervical cancer is the second leading cause of cancer morbidity and mortality in Nigeria. To reduce the burden of cervical cancer in Nigeria, female health…

  4. Artikel Jurnal

    Health technology reassessment and disinvestment instruments: a scoping review

    David Aluga; Shibu Shrestha; Claire Gorry dkk.

    Health Research Policy and Systems, Vol. 24 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract Introduction Evidence on safety, clinical and cost-effectiveness forms a key part of Health Technology Assessment (HTA) value appraisal for new health technologies and is often used to inform reimbursement and market access decisions. However, value may depreciate over the lifecycle of…